Emovis GmbH
- Address
- Bezirk Charlottenburg Wilmersdorf, Wilmersdorfer Strasse 79, Charlottenburg, 10629 Berlin, Germany
Emovis GmbH - Multispecialty Clinical Research Center
Emovis GmbH is a comprehensive clinical research facility specializing in phase 2 through phase 4 clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in cardiometabolic disorders, chronic pain management, and immunological conditions, conducting both early-stage dose-finding studies and large-scale cardiovascular outcomes trials.
- Cardiovascular and renal disease research, including chronic kidney disease with hypertension, heart failure with preserved ejection fraction, and hypercholesterolemia management
- Pain disorders and chronic inflammatory conditions, encompassing chronic low back pain, osteoarthritis, diabetic peripheral neuropathy, polymyalgia rheumatica, and functional cardiovascular disorders
- Dermatological and immunological disorders, including moderate to severe plaque psoriasis, chronic spontaneous urticaria, alopecia areata, and lichen simplex chronicus
- Metabolic disorders and obesity-related conditions, featuring studies on hypertension with obesity, cardiovascular outcomes in obesity, and metabolic syndrome
The research center conducts sophisticated trials in neurodegenerative and psychiatric disorders, including early Alzheimer's disease with inflammatory biomarkers and major depressive disorder. Emovis also maintains active programs in gastrointestinal diseases such as Crohn's disease and ulcerative colitis, respiratory conditions including COPD and infectious disease prevention (influenza, RSV, tuberculosis), and sleep medicine with studies on insomnia and menopause-related sleep disturbances. The facility demonstrates capabilities in evaluating novel therapeutic modalities including biologics, small molecules, mRNA vaccines, and medical cannabis formulations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Emovis GmbH
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients with Hyperuricemia | LG Chem Ltd. | Phase III | Not Recruiting | Apr 2024 | Apr 2025 |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine | 1 | Unknown | 2024-09-30 | 2024-09-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.